MedTrace Logo

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

NCT02478502 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-02-02

No results posted yet for this study

Summary

Germ cell tumors belong to the most chemosensitive malignancies. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer.

Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical activity in patients with metastatic and progressive germ cell tumors.

Conditions

  • Testicular Cancer

Interventions

DRUG

cabazitaxel

cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Jan Oldenburg, MD, PhD · University Hospital, Akershus

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Denmark
  • Italy
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02478502 on ClinicalTrials.gov